Hollis-Eden Pharmaceuticals, Inc.

Neumune improves survival in non-human primates after radiation exposure

Published in Healthcare Finance, Tax and Law Weekly, October 27th, 2004

Hollis-Eden Pharmaceuticals, Inc., (HEPH) released data from a pilot study indicating that non-human primates treated with Neumune (HE2100) after exposure to a high dose of radiation experienced an improved rate of survival over animals receiving placebo or no treatment.

Neumune is an investigational immune regulating hormone being developed by Hollis-Eden as a treatment for acute radiation injury pursuant to the U.S. Food and Drug Administration (FDA) "animal rule" for countermeasures to weapons of mass destruction.

Under the FDA animal rule, because it would be unethical to conduct efficacy studies in humans, results in animals are used as a...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2004-10-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry